Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry.

Tessa StraatmijerFiona D M van SchaikAlexander G L BodelierMarijn VisschedijkAnnemarie C de VriesCyriel Y PonsioenMarieke PierikAdriaan A van BodegravenRachel L WestNanne K H de BoerNidhi SrivastavaTessa E H RomkensJildou HoekstraBas OldenburgGerard DijkstraJanneke C van der WoudeMark LöwenbergZlatan MujagicVince B C BiemansAndrea E van der Meulen-de JongMarjolijn Duijvestein

Published in: Alimentary pharmacology & therapeutics (2022)

Tofacitinib was effective in 31.8% of patients after 24 months of treatment.

Keyphrases

ulcerative colitis
rheumatoid arthritis
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
patient reported outcomes
replacement therapy
smoking cessation